COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

Blood Transfus. 2020 May;18(3):167-169. doi: 10.2450/2020.0083-20. Epub 2020 Apr 8.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Acute Kidney Injury / complications
  • Betacoronavirus*
  • Blood Coagulation Disorders / blood*
  • Blood Coagulation Disorders / drug therapy
  • Blood Coagulation Disorders / physiopathology
  • Comorbidity
  • Coronavirus Infections / blood*
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / physiopathology
  • Factor Xa Inhibitors / therapeutic use
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolytic Agents / therapeutic use
  • Hemostasis
  • Heparin / therapeutic use
  • Humans
  • Italy
  • Pandemics
  • Pneumonia, Viral / blood*
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / physiopathology
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / prevention & control
  • Societies, Medical
  • Thrombosis / blood
  • Thrombosis / drug therapy

Substances

  • Factor Xa Inhibitors
  • Fibrin Fibrinogen Degradation Products
  • Fibrinolytic Agents
  • fibrin fragment D
  • Heparin

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2